Csl Limited · ASX:CSL
Csl — Shareholder Meeting (October 2007)
18 slides from Csl's shareholder meeting presentation, Oct 17, 2007
Slide 1: Chairman's Address and Managing Director's Presentation
For personal use only 17 October 2007 To: The Manager Companies Company Announcements Office Australian Stock Exchange Limited Dear Sir/Madam CHAIRMAN’S ADDRESS AND MANAGING DIRECTOR’S PRESENTATION Please find attached copies of the Chairman’s Address and Managing Director’s presentation slides to b
Slide 2: Chairman's Address
CSL LIMITED CHAIRMAN’s ADDRESS ANNUAL GENERAL MEETING 17 OCTOBER 2007 For personal use only I am very pleased to be able to report that the strong trading performance of our plasma products business and successful Australian and international launches of the GARDASIL vaccine against cervical cancer
Slide 3: Business Reports
BUSINESS REPORTS Let me now briefly comment on our business activities which include the operations of CSL Behring, CSL Bioplasma, CSL Biotherapies, and our global research and development programs. For personal use only CSL Behring sales revenue increased 8% on the previous financial year to $2.6 b
Slide 4: Chairman's Address (continued)
underpinned by the work in progress to significantly increase vaccine production at our Melbourne plant. Research and development investment increased 18% this year to $191 million. Our focus is protein-based medicines purified from human plasma, made from traditional sources (as with influenza vacc
Slide 5: Currency translation and thanks to staff
When consolidating net profit of our international businesses for financial reporting purposes there are non cash implications of notionally translating their foreign currency earnings into Australian dollars as exchange rates move from one financial reporting period to another. Given translation fo
Slide 6: For personal use only
iS, £ = : > q —| } S YW) = L) : | ~~ a
Slide 7: Key Operational Highlights
Key Operational Highlights For personal use only • Strong global demand for plasma therapies continues • Successful first full year of GARDASIL® rollout by Merck • Commonwealth Government funding of GARDASIL® in Australia • Extension of Helixate® supply agreement to 2017 • Privigen™ (10% liquid IVIG
Slide 8: Net Profit After Tax
Net Profit After Tax For personal use only $M 600 $521m 500 +48% Sanofi Settlement 400 $351m 300 200 Aventis contingent Provision 100 Reported Reported NPAT NPAT $117m $539m 0 Jun 06 Jun 07 NPAT for the 12 month period 3
Slide 9: Sales – Geographic Breadth
Sales – Geographic Breadth For personal use only Global Sales $3.2bn Australia Asia 13% North America 8% 38% Rest of World 4% Europe 37% 4
Slide 10: Sales – By Business Unit
Sales – By Business Unit For personal use only CSL Bioplasma CSL Biotherapies $211m $317m CSL Behring $2,645m 5
Slide 11: CSL Behring – Therapy Group
CSL Behring – Therapy Group For personal use only +13% US$2.1bn Other Immuno- globulins Wound H Critical Care Pd Coag Rec Coag Jun 06 Jun 07 Sales for the 12 month period 6
Slide 12: CSL Behring - Strong EBITDA Margin
CSL Behring - Strong EBITDA Margin For personal use only 31% 15% Inventory Discount 2004 2005 2006 2007 7
Slide 13: Sales – By Business Unit
Sales – By Business Unit For personal use only CSL Bioplasma CSL Biotherapies $211m $317m CSL Behring $2,645m 8
Slide 14: GARDASIL Australia and Influenza Vaccine
GARDASIL® Australia For personal use only • $100m in sales • Strong start to school based program • 18 to 26 year old GP based catch-up program commenced July 2007 Influenza Vaccine • US FDA marketing approval for Afluria® • Launch anticipated October 2007 • Significant phase IV studies required by
Slide 15: Sales – By Business Unit
Sales – By Business Unit For personal use only CSL Bioplasma CSL Biotherapies $211m $317m CSL Behring $2,645m 10
Slide 16: R&D Investment
R&D Investment For personal use only $Am FY2008 200 $191 ~$220m New Product Development 150 100 Market development 50 Life Cycle Management 0 FY2005 FY2006 FY2007 11
Slide 17: Growth Strategy
Growth Strategy For personal use only • Novel Biotech products • ISCOMATRIX® • Novel plasma adjuvant products • Market Development • Influenza vaccine • Advanced IG products Global Specialty Biopharmaceutical • HPV royalties • Plasma sector stability • GARDASIL® • Maintaining narrow global focus (Au
Slide 18: For personal use only
iS, £ = : > q —| } S YW) = L) : | ~~ a